RxDoctor Payments Data

Charles Hensleigh, MD

Family Medicine · Ashland, ALNPI 1528051133

Payments from drug & device makers

$8,903in general payments, 2019–2025

Across 541 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Pfizer$781
  • Novartis$618
  • AstraZeneca$532
  • Johnson & Johnson$511
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,67597%
  • Education$2283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,903 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$306,422
Medicare patients
409
Services billed
18,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide338$377,921
OzempicSemaglutide186$246,135
EliquisApixaban312$215,018
FarxigaDapagliflozin Propanediol274$192,987
JardianceEmpagliflozin160$165,929
LinzessLinaclotide196$131,297
RybelsusSemaglutide91$98,246
TrulicityDulaglutide81$92,991
XareltoRivaroxaban107$66,205
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$63,527
Tresiba Flextouch U-100Insulin Degludec58$57,057
CreonLipase/Protease/Amylase30$48,994
MyrbetriqMirabegron102$47,020
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$40,097
Soliqua 100-33Insulin Glargine/Lixisenatide41$39,400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$492$470,911419 claims
Novo NordiskOzempic, Rybelsus, Tresiba$1,249$357,739313 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$532$235,790360 claims
PfizerEliquis, Premarin$781$227,329346 claims
AbbVieLinzess, Creon, Qulipta, Restasis$1,060$209,392258 claims
Boehringer IngelheimJardiance$241$165,929160 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$107$111,925176 claims
Johnson & JohnsonXarelto, Invokana$511$79,030121 claims
Astellas Pharma US IncMyrbetriq$216$47,020102 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$229$40,59083 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$302$39,40041 claims
NovartisEntresto$618$31,40026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Ashland

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →